Superstring Capital Management’s Oric Pharmaceuticals ORIC Stock Holding History

Superstring Capital Management’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.4M	Buy	406,077 +290,843	+252%	+$2.64M	2.78%	15
2026 Q1	$1.46M	Sell	115,234 -140,136	-55%	-$1.59M	1.04%	25
2025 Q4	$2.09M	Buy	255,370 +166,024	+186%	+$1.91M	1.12%	27
2025 Q3	$1.07M	Sell	89,346 -255,576	-74%	-$2.69M	1.06%	29
2025 Q2	$3.5M	Sell	344,922 -474,272	-58%	-$3.18M	4.15%	12
2025 Q1	$4.57M	Sell	819,194 -761,551	-48%	-$6.66M	5.44%	8
2024 Q4	$12.8M	Buy	1,580,745 +631,223	+66%	+$5.79M	11.05%	1
2024 Q3	$9.73M	Buy	+949,522	New	+$9.39M	8.52%	5

Other funds holding ORIC

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Superstring Capital Management's ORIC Position: Q2 2026 in Review

Superstring Capital Management increased its Oric Pharmaceuticals (ORIC) stake by 252% in Q2 2026, buying an estimated $2.64M and bringing the position to 406,077 shares worth $4.4M. The position accounts for 2.78% of the portfolio, ranked #15.

Superstring Capital Management first reported a position in ORIC in Q3 2024 and has held it in 8 quarters since. The position peaked at $12.8M in Q4 2024. 181 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

Superstring Capital Management held 406,077 shares of Oric Pharmaceuticals worth $4.4M as of Q2 2026.
Superstring Capital Management bought 290,843 Oric Pharmaceuticals shares in Q2 2026, an estimated $2.64M.
Oric Pharmaceuticals made up 2.78% of Superstring Capital Management's portfolio in Q2 2026, its #15 holding.
Superstring Capital Management first reported a position in Oric Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
Superstring Capital Management's Oric Pharmaceuticals position peaked at $12.8M in Q4 2024.
181 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Superstring Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.